Vol. 3 No. 7 (2023)
Reimbursement Reviews

Caplacizumab (Cablivi)

Published July 13, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses caplacizumab (Cablivi) for injection, powder for solution (11 mg), IV or subcutaneous.
  • Indication: For the treatment of adults with acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy.